The other thing to keep in mind is that we still need to hear from the EMA.  Their timeframes for a turnaround to BTD applications may be longer, but it certainly underscores how aggressive the FDA currently is in granting approval to applications that warrant it.

And, as someone had also mentioned previously, it demonstrates that RVX appears to have a positive relationship with the FDA no doubt because RVX plays by the rules. I sense RVX management's mindset is more on the science than on market cap and that may help it come across to regulatory bodies in, well, a good way.  Science is the main driver, but intangibles like politics, decorum, etc. surely also play a role.

Really interested to see what news the next few weeks and months will bring.